FDA experts gun down a big part of Sanofi's pitch for their controversial vaccine
Sanofi has taken its controversial dengue vaccine to the FDA, but a panel of outside experts just handed down a mixed decision that could reduce — or even eliminate — any market potential it may have in the US.
In a series of votes Thursday afternoon, the FDA’s vaccine advisers handed down split votes on safety and effectiveness for the pharma giant’s target population, from 9 to 45. They lost the efficacy vote 6 to 7, with one abstention, with a straight 7-7 split on safety.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
